How many shares did Aurinia repurchase and at what price?

Aurinia repurchased 5.0 million shares for $74.9 million during the first six months of 2026, representing an average price of $14.98 per share. These repurchases were executed under the company's Share Repurchase Plan.

Where did Aurinia source the cash for these buybacks?

The company funded the $74.9 million in share repurchases from its operating cash flows, which totaled $85.1 million for the first half of 2026. This represented a 87% increase in operating cash flow compared to the same period in 2025.

What was Aurinia's financial performance during this period?

Aurinia reported strong results with net income of $71.8 million (up 60% year-over-year) and total revenue of $160.9 million (up 21% year-over-year) for H1 2026. Diluted EPS was $0.53, up 66% versus the prior-year period, driven largely by LUPKYNIS product sales of $153.0 million.

Does Aurinia have remaining authorization to continue buybacks?

The filing does not disclose the total authorization amount or remaining authorization under the Share Repurchase Plan, so the scope of future repurchase capacity cannot be determined from this earnings announcement.

Why do companies repurchase shares?

Share repurchases can reduce share count, thereby supporting or boosting earnings per share (EPS) when profitability is stable or growing. They also represent a return of capital to shareholders and can offset dilution from equity compensation plans.

How did the buyback affect Aurinia's share count?

Despite the repurchase of 5.0 million shares, Aurinia's outstanding common share count increased slightly from 132.3 million at December 31, 2025 to 132.9 million at June 30, 2026, due to the issuance of shares for equity awards net of tax withholding payments offsetting the net reduction.

AUPH 8-K Filed 2026-08-06 Execution disclosure

Aurinia repurchased 5.0M shares at $14.98 average in H1 2026

Biopharma company spent $74.9M on buybacks during first half, as revenue grew 21% on LUPKYNIS sales strength

Shares repurchased5.0M

Avg price paid$14.98

MechanismShare Repurchase Plan (Rule 10

What the filing says

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) repurchased 5.0 million common shares for $74.9 million during the six months ended June 30, 2026, according to the company's earnings release filed as an 8-K on August 6, 2026. The repurchases were executed under the company's Share Repurchase Plan using cash flows from operating activities.

The execution occurred as Aurinia delivered strong financial results, with net income of $71.8 million and diluted earnings per share of $0.53 for the first half of 2026, up 60% and 66% respectively year-over-year. Total revenue reached $160.9 million, up 21% from $132.5 million in the same period in 2025, driven principally by LUPKYNIS net product sales of $153.0 million.

As of June 30, 2026, Aurinia's cash position stood at $443.1 million in cash, cash equivalents, restricted cash and investments, compared to $398.0 million at year-end 2025. The company reiterates its 2026 total revenue guidance of $315 million to $325 million. The execution mechanism was not explicitly specified in the filing but is consistent with Rule 10b-18 open-market purchases under a formal repurchase plan.

For the six months ended June 30, 2026, cash outflows from financing activities were $48.9 million, which included the repurchase of 5.0 million of the Company's common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $32.7 million. — Aurinia Pharmaceuticals Inc. 8-K filing · View on SEC EDGAR →

What this means

Aurinia's $74.9 million buyback represents capital allocation to shareholders amid strong profitability growth. The repurchase of 5.0 million shares reduces the company's outstanding share count from 132.3 million shares at year-end 2025 to 132.9 million at mid-year 2026 (reflecting both the buyback and equity awards). At an average price of $14.98 per share, the execution occurred at a multiple substantially below historical valuations, though the filing provides no explicit authorization amount or program termination language, leaving remaining authorization unknown.

Frequently asked questions

How many shares did Aurinia repurchase and at what price?: Aurinia repurchased 5.0 million shares for $74.9 million during the first six months of 2026, representing an average price of $14.98 per share. These repurchases were executed under the company's Share Repurchase Plan.
Where did Aurinia source the cash for these buybacks?: The company funded the $74.9 million in share repurchases from its operating cash flows, which totaled $85.1 million for the first half of 2026. This represented a 87% increase in operating cash flow compared to the same period in 2025.
What was Aurinia's financial performance during this period?: Aurinia reported strong results with net income of $71.8 million (up 60% year-over-year) and total revenue of $160.9 million (up 21% year-over-year) for H1 2026. Diluted EPS was $0.53, up 66% versus the prior-year period, driven largely by LUPKYNIS product sales of $153.0 million.
Does Aurinia have remaining authorization to continue buybacks?: The filing does not disclose the total authorization amount or remaining authorization under the Share Repurchase Plan, so the scope of future repurchase capacity cannot be determined from this earnings announcement.
Why do companies repurchase shares?: Share repurchases can reduce share count, thereby supporting or boosting earnings per share (EPS) when profitability is stable or growing. They also represent a return of capital to shareholders and can offset dilution from equity compensation plans.
How did the buyback affect Aurinia's share count?: Despite the repurchase of 5.0 million shares, Aurinia's outstanding common share count increased slightly from 132.3 million at December 31, 2025 to 132.9 million at June 30, 2026, due to the issuance of shares for equity awards net of tax withholding payments offsetting the net reduction.

execution biopharmaceutical share-repurchase-plan lupkynis profitability-driven

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.